睿智医药加码小核酸药物研发领域

Core Insights - Ruizhi Pharmaceutical Technology Co., Ltd. has developed two automated integrated micro-flow synthesis systems based on its "Super Limit Intelligent Manufacturing" platform, which are currently applied internally to enhance R&D in ADC and small nucleic acid drug fields [1][2] Group 1: Technology and Innovation - The internal application of the Super Limit Intelligent Manufacturing platform focuses on two main areas: enhancing the coupling process for antibody-drug conjugates (ADCs) and synthesizing nucleoside monomers for oligonucleotide drugs, significantly improving development efficiency and overall yield [1] - The ADC drug process development time can be reduced by 70%, while the cost of synthesizing nucleoside monomers can be lowered by over 40% [2] Group 2: Strategic Partnerships and Market Positioning - The drug manufacturing system was jointly released by Ruizhi Pharmaceutical and East China Normal University, emphasizing the establishment of a joint laboratory to improve the transition from laboratory R&D to industrial production [2] - The company is positioning its business around "new modalities (including small nucleic acids)" and "ecological investment," aiming to create more opportunities in the small nucleic acid sector through strategic partnerships with multiple companies [2]